Form 8-K · Current report
News Corp 8-K, filed Sep 3, 2026
- Filed
- CIK
- 0001564708
- Accession no.
- 0001564708-26-000194
Summary
News Corp disclosed to the Australian Securities Exchange that it bought back 54,641 Class A common shares on September 2, 2026 for about US$1.69 million, part of its program authorized July 15, 2025 to repurchase up to US$1 billion of Class A and Class B common stock. The company said it has purchased approximately US$458.3 million worth of shares under the program to date.
Key points
- News Corp repurchased 54,641 Class A common shares on September 2, 2026, for about US$1.69 million, with a high price of US$31.32 and a low of US$30.54 that day.
- Cumulative buy-backs under the program total 11,505,527 shares for approximately US$297.9 million, with roughly US$458.3 million of consideration paid to date.
- The repurchase program, authorized July 15, 2025, allows up to US$1 billion in aggregate of Class A and Class B common stock, with Goldman Sachs & Co. LLC as broker.
- No ASX-listed CDIs are being repurchased under the program.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 8.01Other Events
- 9.01Financial Statements and Exhibits
From the filing
Item 8.01 Other Events. As previously reported, under News Corporation's (the "Company's") stock repurchase program (the "Repurchase Program"), the Company is authorized to acquire from time to time up to $1 billion in the aggregate of the Company's outstanding shares of Class A common stock and Class B common stock. Under the rules of the Australian Securities Exchange (the "ASX"), the Company is required to provide to the ASX, on a daily basis, disclosure of transactions pursuant to the Repurchase Program, if any. The Company also discloses information concerning the Repurchase Program in the Company's quarterly and annual reports. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.